Leo Pharma

Trending Articles

  1. IMPACT CKD model reveals the escalating toll of chronic kidney disease The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
  5. ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Digital

Is there anybody out there? Making relationships real in a digital age

Takeaways from Chris Moore’s Summit keynote with LEO Pharma’s Monica Shaw and Boehringer Ingelheim’s Timmo Rousku Andersen

Astellas transfers its global dermatology business to LEO Pharma

This comes just days after Astellas moved to buy regenerative medicines company Ocata Therapeutics
Research & Development

arGEN-X and LEO Pharma sign deal to develop antibody-based treatments for skin conditions

Dutch biotechnology company could potentially receive nearly €105m in payments
Research & Development

LEO Pharma and University of Queensland enter skin cancer treatments collaboration

Agreement will cover areas of skin cancer in which LEO Pharma is already active
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Drug approvals: more numerous but niche

After many years of low approval rates, in 2012 more than 30 new drugs were approved by the European Medicines Agency. Although many of them were niche products, some were for diseases with large patient populations, such as diabetes and various forms of cancer
Research & Development

LEO Pharma unveils collaboration strategy for dermatology treatments

To form five long-term partnerships in four countries
Finance

Danish firms withdraw drugs from Greece

Novo Nordisk and Leo Pharma protest against price cuts of 25% in Greece
Subscribe now